Related Experiment Videos
MDM2 oncogene as a novel target for human cancer therapy
1Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Ruiwen.Zhang@ccc.uab.edu
Abstract:
The MDM2 oncogene was first cloned as an amplified gene on a murine double-minute chromosome in the 3T3DM cell line, a spontaneously transformed derivative of BALB/c 3T3 cells. The MDM2 oncogene has now been shown to be amplified or overexpressed in many human cancers. It also has been suggested that MDM2 levels are associated with poor prognosis of several human cancers. The most exciting finding is the MDM2-p53 autoregulatory feedback loop that regulates the function of the p53 tumor suppressor gene. The MDM2 gene is a target for direct transcriptional activation by p53, and the MDM2 protein is a negative regulator of p53. The MDM2 oncoprotein binds to the p53 protein, inhibiting p53 functions as a transcription factor and inducing p53 degradation. The p53 tumor suppressor has an important role in cancer therapy, with p53-mediated cell growth arrest and/or apoptosis being major mechanisms of action for many clinically used cancer chemotherapeutic agents and radiation therapy. Therefore, the MDM2-p53 interaction may be a target for cancer therapy. In addition, the negative regulation of p53 by MDM2 may limit the magnitude of p53 activation by DNA damaging agents, thereby limiting their therapeutic effectiveness. If the MDM2 feed-back inhibition of p53 is interrupted, a significant increase in functional p53 levels will increase p53-mediated therapeutic effectiveness. Several approaches have now been tested using this strategy, including polypeptides targeted to MDM2-p53 binding domain and antisense oligonucleotides that specifically inhibit MDM2 expression. In addition to the interaction with p53, the MDM2 protein has been found to have interactions with other cellular proteins such as pRb and E2F-1. Although the exact function and significance of these interactions are not fully understood, the p53-independent functions of MDM2 may have a role in cancer etiology and progression, indicating that the MDM2 oncogene is a potential molecular target for cancer therapy.
Insights
The MDM2 oncogene, amplified in many cancers, negatively regulates the p53 tumor suppressor. Inhibiting this MDM2-p53 interaction enhances cancer therapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- The MDM2 oncogene is amplified and overexpressed in numerous human cancers, often correlating with poor prognosis.
- MDM2 forms a critical autoregulatory feedback loop with the p53 tumor suppressor gene.
- p53 is a key player in cancer therapy, mediating apoptosis and cell cycle arrest.
Purpose of the Study:
- To investigate the MDM2-p53 autoregulatory feedback loop as a potential cancer therapeutic target.
- To explore strategies for interrupting MDM2's negative regulation of p53 to enhance therapeutic efficacy.
Main Methods:
- Analysis of the MDM2-p53 interaction and its role in regulating p53 function.
- Evaluation of therapeutic strategies targeting the MDM2-p53 binding domain.
- Assessment of antisense oligonucleotides for inhibiting MDM2 expression.
Main Results:
- MDM2 protein binds to p53, inhibiting its transcriptional activity and promoting its degradation.
- Interruption of the MDM2-p53 feedback loop significantly increases functional p53 levels.
- Therapeutic approaches like polypeptides and antisense oligonucleotides targeting this interaction show promise.
Conclusions:
- The MDM2-p53 interaction is a viable target for novel cancer therapies.
- Enhancing p53 activity by inhibiting MDM2 can improve the effectiveness of existing cancer treatments.
- p53-independent functions of MDM2 also warrant further investigation for cancer therapy development.